Tokyo, Japan – (Noofambar 15, 2022) – Daiichi Sankyo (TSE: 4568) ayaa maanta ku dhawaaqday in tijaabo lagu qiimaynayo waxtarka iyo badbaadada tallaalka xoojinta ah ee DS-5670, oo ah tallaalka mRNA ee ka hortagga cudurka faafa ee novel coronavirus (COVID) -19) waxaa soo saaray Daiichi Sankyo (ka dib, tijaabada tallaalka xoojisa), barta ugu dambeysa ee dhamaadka waa la gaaray.Tijaabada tallaalka xoojisay waxaa ka mid ahaa ku dhawaad 5,000 oo qof oo waaweyn iyo maadooyin caafimaad qaba oo Jabbaan ah kuwaas oo dhammeeyay taxanaha aasaasiga ah (laba qiyaasood) ee tallaallada mRNA ee lagu ansixiyay Japan ugu yaraan lix bilood ka hor is-diiwaangelinta.Bishii Janaayo 2022, tijaabada waxaa loo bilaabay sidii weji 1/2/3 tijaabo ah si loo qiimeeyo waxtarka iyo badbaadada tallaalka xoojisa ee DS-5670 iyadoo la adeegsanayo tallaalada mRNA ee loo oggolaaday Japan sidii xakamaynta.GMFR ee ka takhalusida titer antibody ka dhanka ah SARS-CoV-2 (cadayska asalka ah) ee dhiiga afar toddobaad kadib tallaalka xoojinta, barta ugu dambeysa ee tijaabada tallaalka xoojinta, waxay muujisay xog sare iyo hoos-u-dhac la'aan DS-5670 tallaallada mRNA ( Cadaadiska asalka ah) ee lagu ansixiyay Japan, gaaritaanka ujeeddadii loogu talagalay.Ma jiro wax walaac ah oo dhinaca ammaanka ah oo la aqoonsaday.Natiijooyinka faahfaahsan ee tijaabada tallaalka xoojinta waxaa lagu soo bandhigi doonaa shirarka tacliinta iyo waraaqaha cilmi-baarista.Iyada oo ku saleysan natiijooyinka tijaabada, Daiichi Sankyo waxay sii wadi doontaa diyaarinta codsiga cusub ee dawada ee tallaalka mRNA bisha Janaayo 2023. Intaa waxaa dheer, Daiichi Sankyo wuxuu qorsheynayaa inuu sameeyo tijaabooyin caafimaad oo tallaalada laba-geesoodka ah ee nooca asalka ah iyo noocyada Omicron ee ka dhanka ah coronaviruses cusub, kuwaas oo sii wada in ay isbedelaan.Daiichi Sankyo waxay ku dadaali doontaa inay xoojiso horumarinta iyo nidaamka wax soo saarka tallaalka mRNA si loo hubiyo sahayda xasilloon waqtiyada caadiga ah iyo sidoo kale bixinta tallaalka degdegga ah haddii ay dillaacaan cudurrada faafa iyo kuwa soo noqnoqda.
Ku saabsan DS-5670 DS-5670 waa tallaal mRNA ah oo ka dhan ah COVID-19 iyadoo la adeegsanayo tignoolajiyada gudbinta nukleic acid cusub oo uu daahfuray Daiichi Sankyo, loogu talagalay in lagu soo saaro unugyada difaaca jirka ee ka soo horjeeda domainka soo-dhoweynta (RBD) ee borotiinka sare ee coronavirus-ka cusub, sidaas darteed la filayo in laga helo ka hortag wanaagsan oo ka dhan ah COVID-19 iyo 2 badbaadada.Intaa waxaa dheer, Daiichi Sankyo waxay higsaneysaa tallaalada mRNA kuwaas oo lagu qaybin karo heerkulka qaboojiyaha (2-8°C)
Waqtiga boostada: Dec-17-2022
